Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
BUSINESS Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
-
REGULATORY MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
-
BUSINESS Santen’s New China Plant Completed, Poised for 2027 Launch
April 17, 2024
-
BUSINESS Jardiance, Ofev Continue to Drive Boehringer’s Global Sales
April 17, 2024
-
BUSINESS Nippon Shinyaku Seeks Uptravi Use in Pediatric PAH in Japan
April 17, 2024
-
BUSINESS Lagevrio’s Smaller Tablet Version Filed in Japan: MSD
April 17, 2024
-
BUSINESS Moderna to File mRNA RSV Vaccine in Japan within 2024: Exec
April 17, 2024
-
REGULATORY PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
-
BUSINESS 80%-Plus Doctors Seek In-Person Meetings with Reps: Lilly Survey
April 16, 2024
-
BUSINESS Meiji Reaffirms 2028 Launch Plan for New Vaccine Site as METI Grants Finalized
April 16, 2024
-
BUSINESS Nxera Grants Pivlaz’s Korean Commercial Rights to Handok
April 16, 2024
-
BUSINESS Vabysmo Set for 2025 Filing for Angioid Streaks after Japan Trial Success
April 16, 2024
-
BUSINESS Xofluza Approved for Pediatric Use in Taiwan: Shionogi
April 16, 2024
-
REGULATORY 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
-
BUSINESS Fujifilm to Invest 180 Billion Yen to Bolster Biologic CDMO Biz in North America
April 15, 2024
-
BUSINESS Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
-
BUSINESS Takeda Files 2-Dose Vial Version of Novavax COVID Vaccine
April 15, 2024
-
BUSINESS MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
-
REGULATORY Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
-
REGULATORY Japan Might Approve 1st Eylea Biosimilar by June, but Not AMD Use
April 15, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…